Physician profile
Brycen Witcher
NPI 1356924476
$9,091.55
in general payments reported to CMS, 2019-2025
16 companies · $3,883 in 2025
The $3,883 reported for 2025 was more than what 88% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $30.58 · 2024: $5,178 · 2025: $3,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134 · Travel and Lodging: $3,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,134.42 |
| Travel and Lodging | $3,957.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,057.65 | 2024-2025 | Proclaim, Eterna, Durata |
| Medtronic, INC. | $2,956.68 | 2024-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Osteocool Rf Ablation System |
| Boston Scientific Corporation | $1,800.03 | 2024-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Spr Therapeutics, INC | $326.40 | 2024 | Sprint Pns System |
| Spinal Simplicity, LLC | $213.09 | 2024-2025 | Ha Minuteman G3-R |
| Nalu Medical, INC. | $145.86 | 2025 | Nalu Neurostimulation System |
| Nevro Corp. | $137.04 | 2024 | Senza |
| Si-Bone, INC. | $115.07 | 2024-2025 | |
| Abbvie INC. | $70.00 | 2025 | |
| Collegium Pharmaceutical, INC. | $58.61 | 2025 | Xtampza |
| Globus Medical, INC. | $58.35 | 2025 | Senza, Vyrsa V1 |
| Vertex Pharmaceuticals Incorporated | $52.70 | 2024 | |
| Novartis Pharmaceuticals Corporation | $35.16 | 2024 | |
| Avanos Medical | $34.33 | 2024 | Coolief* Cooled Radiofrequency |
| Astrazeneca Pharmaceuticals LP | $17.42 | 2023 | Farxiga |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.16 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brycen Witcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.